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background: The combined use of warfarin and aspirin (ASA) in patients with atrial fibrillation (AF) has been shown to significantly increase the 
risk of bleeding complications without the benefit of added stroke reduction. Such data is lacking for the direct thrombin inhibitor dabigatran and 
the factor Xa inhibitor rivaroxaban.
methods: We retrospectively analyzed outcomes in 8,264 patients with AF who were treated with warfarin, dabigatran or rivaroxaban. Chi-square 
and exact chi-square tests were used to compare the rates of bleeding and stroke/TIA when using monotherapy to those when using combination 
therapy with ASA.
results: Of 8,264 patients, 39% were on monotherapy and 61% were on a combination therapy with ASA (Table). Mean age of patients on warfarin 
was significantly higher than dabigatran and rivaroxaban. Overall, the rate of stroke using monotherapy was similar among dabigatran, rivaroxaban 
and warfarin. The addition of ASA did not result in further stroke reduction in any combination, but was associated with significantly higher rate of 
stroke in the warfarin group. The overall bleeding rate was higher in the warfarin group compared to dabigatran or rivaroxaban. The addition of ASA 
significantly increased bleeding risk with all three agents, but there was proportionately greater effect with the new anticoagulants.
conclusion: Combining ASA with novel anticoagulants does not provide additional benefit in stroke reduction and is associated with increased risk 
of bleeding complications.
